SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

YOUNG WILLIAM

(Last)

(First)

(Middle)

BIOGEN IDEC INC.

133 BOSTON POST ROAD

(Street)

WESTON

02493

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/27/2011

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/27/2011		M⁽¹⁾		12,500	A	$47.55	39,359	D
Common Stock	09/27/2011		M⁽¹⁾		3,125	A	$46.99	42,484	D
Common Stock	09/27/2011		M⁽¹⁾		5,950	A	$52.22	48,434	D
Common Stock	09/27/2011		M⁽¹⁾		5,700	A	$59.17	54,134	D
Common Stock	09/27/2011		M⁽¹⁾		5,975	A	$53.43	60,109	D
Common Stock	09/27/2011		S⁽¹⁾		33,250	D	$96.14	26,859	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)⁽²⁾	$47.55	09/27/2011		M⁽¹⁾			12,500	⁽³⁾	01/09/2016	Common Stock	12,500	$0	0	D
Employee Stock Option (Right to Buy)⁽²⁾	$46.99	09/27/2011		M⁽¹⁾			3,125	⁽⁴⁾	05/24/2016	Common Stock	3,125	$0	0	D
Stock Option (Right to Buy)	$52.22	09/27/2011		M⁽¹⁾			5,950	⁽⁵⁾	05/30/2017	Common Stock	5,950	$0	0	D
Stock Option (Right to Buy)	$59.17	09/27/2011		M⁽¹⁾			5,700	06/19/2009	06/18/2018	Common Stock	5,700	$0	0	D
Stock Option (Right to Buy)⁽²⁾	$53.43	09/27/2011		M⁽¹⁾			5,975	06/03/2010	06/02/2019	Common Stock	5,975	$0	0	D

Explanation of Responses:

1. Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities and Exchange Act of 1934.

2. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).

3. Immediately exercisable for all the option shares on grant date of 01/09/2006 subject to Issuer's repurchase rights which lapse on 01/09/2007.

4. Options will vest in their entirety on 05/25/2007 provided that the Reporting Owner is then a member of the Issuer's Board of Directors.

5. Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc.

	Aras Lapinskas, Attorney in Fact for William D. Young	09/29/2011
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.